Abstract:OBJECTIVES:Malignant melanoma is a highly malignant and heterogeneous skin cancer. Although immunotherapy has improved survival rates, the inhibitory effect of tumor microenvironment has weakened its efficacy. To improve survival and treatment strategies, we need to develop immune-related prognostic models. Based on the analysis of the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Sequence Read Archive (SRA) database, this study aims to establish an immune-related prognosis prediction model, and to evaluate the tumor immune microenvironment by risk score to guide immunotherapy.METHODS:Skin cutaneous melanoma (SKCM) transcriptome sequencing data and corresponding clinical information were obtained from the TCGA database, differentially expressed genes were analyzed, and prognostic models were developed using univariate Cox regression, the LASSO method, and stepwise regression. Differentially expressed genes in prognostic models confirmed by real-time reverse transcription PCR (real-time RT-PCR) and Western blotting. Survival analysis was performed by using the Kaplan-Meier method, and the effect of the model was evaluated by time-dependent receiver operating characteristic curve as well as multivariate Cox regression, and the prognostic model was validated by 2 GEO melanoma datasets. Furthermore, correlations between risk score and immune cell infiltration, Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) score, immune checkpoint mRNA expression levels, tumor immune cycle, or tumor immune micro-environmental pathways were analyzed. Finally, we performed association analysis for risk score and the efficacy of immunotherapy.RESULTS:We identified 4 genes that were differentially expressed in TCGA-SKCM datasets, which were mainly associated with the tumor immune microenvironment. A prognostic model was also established based on 4 genes. Among 4 genes, the mRNA and protein levels of killer cell lectin like receptor D1 (KLRD1), leukemia inhibitory factor (LIF), and cellular retinoic acid binding protein 2 (CRABP2) genes in melanoma tissues differed significantly from those in normal skin (all P<0.01). The prognostic model was a good predictor of prognosis for patients with SKCM. The patients with high-risk scores had significantly shorter overall survival than those with low-risk scores, and consistent results were achieved in the training cohort and multiple validation cohorts (P<0.001). The risk score was strongly associated with immune cell infiltration, ESTIMATE score, immune checkpoint mRNA expression levels, tumor immune cycle, and tumor immune microenvironmental pathways (P<0.001). The correlation analysis showed that patients with the high-risk scores were in an inhibitory immune microenvironment based on the prognostic model (P<0.01).CONCLUSIONS:The immune-related SKCM prognostic model constructed in this study can effectively predict the prognosis of SKCM patients. Considering its close correlation to the tumor immune microenvironment, the model has some reference value for clinical immunotherapy of SKCM.

Identification of an anoikis-related gene signature and characterization of immune infiltration in skin cutaneous melanoma

Characterization of M6a-Related Genes Landscape in Skin Cutaneous Melanoma to Aid Immunotherapy and Assess Prognosis

New Prognostic Biomarkers and Drug Targets for Skin Cutaneous Melanoma Via Comprehensive Bioinformatic Analysis and Validation

The Identification of the Metabolism Subtypes of Skin Cutaneous Melanoma Associated with the Tumor Microenvironment and the Immunotherapy

Identification of Potential Prognostic Biomarkers Associated With Cancerometastasis in Skin Cutaneous Melanoma

Identification and Validation of Three Risk Models in Skin Melanoma Based on Bioinformatics Analysis

Development and Validation of an Immune-Related Gene Pair Signature in Skin Cutaneous Melanoma

Identification of Immune-Related Biomarkers Associated with Tumorigenesis and Prognosis in Skin Cutaneous Melanoma.

CXC Chemokines as Therapeutic Targets and Prognostic Biomarkers in Skin Cutaneous Melanoma Microenvironment

Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma

Identification of anoikis-related subtypes and development of risk stratification system in skin cutaneous melanoma

Identification of Genes Related to Immune Infiltration in the Tumor Microenvironment of Cutaneous Melanoma

Construction and Identification of an NLR-Associated Prognostic Signature Revealing the Heterogeneous Immune Response in Skin Cutaneous Melanoma

The combination of single-cell and RNA sequencing analysis decodes the melanoma tumor microenvironment and identifies novel T cell-associated signature genes

Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanoma

Exploration of the immune cell infiltration-related gene signature in the prognosis of melanoma

Identification of Therapeutic Targets and Prognostic Biomarkers Among Integrin Subunits in the Skin Cutaneous Melanoma Microenvironment

Analysis on Tumor Immune Microenvironment and Construction of a Prognosis Model for Immune-Related Skin Cutaneous Melanoma.

Unveiling the link between inflammasomes and skin cutaneous melanoma: Insights into expression patterns and immunotherapy response prediction.

Establishment of skin cutaneous melanoma prognosis model based on vascular mimicry risk score

Based on Scrna-Seq and Bulk RNA-seq to Establish Tumor Immune Microenvironment-Associated Signature of Skin Melanoma and Predict Immunotherapy Response